Nuvalent (NASDAQ:NUVL) Hits New 1-Year High – Time to Buy?

Nuvalent, Inc. (NASDAQ:NUVL)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $122.88 and last traded at $122.8550, with a volume of 13794712 shares trading hands. The stock had previously closed at $88.49.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s all-cash acquisition offer values Nuvalent at roughly $10.6 billion and implies a meaningful premium to recent trading levels, giving shareholders a clear exit price. Reuters article on GSK deal
• Positive Sentiment: Analysts and market commentary suggest the deal makes strategic sense for GSK because Nuvalent brings a late-stage lung cancer pipeline, reinforcing investor confidence that the transaction is real and financially significant. WSJ article on GSK deal
• Neutral Sentiment: Several law firms have launched investigations into whether the sale process and $124.00 price are fair to shareholders, which could create some headline noise but does not change the announced deal terms yet. Business Wire article on investigation
• Neutral Sentiment: Wells Fargo and other brokers trimmed ratings after the takeover announcement, but their updated price targets remain near the deal value, so these moves are unlikely to outweigh the acquisition news. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly pressure sentiment by reinforcing that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Wall Street Analysts Forecast Growth

NUVL has been the topic of a number of analyst reports. Leerink Partners set a $165.00 target price on Nuvalent in a report on Wednesday, June 3rd. Stifel Nicolaus set a $124.00 target price on Nuvalent in a report on Tuesday. Robert W. Baird set a $122.85 target price on Nuvalent in a report on Tuesday. Truist Financial set a $124.00 target price on Nuvalent in a report on Tuesday. Finally, Raymond James Financial cut Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $131.15.

Nuvalent Stock Up 0.1%

The firm has a fifty day moving average price of $103.44 and a 200-day moving average price of $103.19. The firm has a market cap of $9.74 billion, a price-to-earnings ratio of -20.35 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period last year, the business posted ($1.18) earnings per share. Equities research analysts anticipate that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Henry E. Pelish sold 3,093 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total transaction of $323,156.64. Following the sale, the insider owned 65,604 shares in the company, valued at $6,854,305.92. This trade represents a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO James Richard Porter sold 30,000 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $88.53, for a total value of $2,655,900.00. Following the sale, the chief executive officer owned 324,879 shares in the company, valued at $28,761,537.87. This trade represents a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 126,953 shares of company stock worth $12,612,264 over the last ninety days. Company insiders own 5.02% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NUVL. GAMMA Investing LLC raised its position in shares of Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after buying an additional 195 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in shares of Nuvalent in the 3rd quarter worth $38,000. NBC Securities Inc. purchased a new position in shares of Nuvalent in the 4th quarter worth $125,000. Finally, KBC Group NV raised its position in shares of Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after buying an additional 297 shares during the period. 97.26% of the stock is owned by hedge funds and other institutional investors.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.